Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Gene-nutrient interactions and susceptibility to human obesity.

Castillo JJ, Orlando RA, Garver WS.

Genes Nutr. 2017 Oct 30;12:29. doi: 10.1186/s12263-017-0581-3. eCollection 2017. Review.

2.

A global evolutionary and metabolic analysis of human obesity gene risk variants.

Castillo JJ, Hazlett ZS, Orlando RA, Garver WS.

Gene. 2017 Sep 5;627:412-419. doi: 10.1016/j.gene.2017.07.002. Epub 2017 Jul 4.

3.

The Niemann-Pick C1 gene interacts with a high-fat diet to promote weight gain through differential regulation of central energy metabolism pathways.

Castillo JJ, Jelinek D, Wei H, Gannon NP, Vaughan RA, Horwood LJ, Meaney FJ, Garcia-Smith R, Trujillo KA, Heidenreich RA, Meyre D, Orlando RA, LeBoeuf RC, Garver WS.

Am J Physiol Endocrinol Metab. 2017 Aug 1;313(2):E183-E194. doi: 10.1152/ajpendo.00369.2016. Epub 2017 May 9.

4.

Differential Association of Niemann-Pick C1 Gene Polymorphisms with Maternal Prepregnancy Overweight and Gestational Diabetes.

Garver WS, de la Torre L, Brennan MC, Luo L, Jelinek D, Castillo JJ, Meyre D, Orlando RA, Heidenreich RA, Rayburn WF.

J Diabetes Obes. 2015;2(1). doi: 10.15436/2376-0494.15.007.

5.
6.

Curcumin reduces cytotoxicity of 5-Fluorouracil treatment in human breast cancer cells.

Ferguson JE, Orlando RA.

J Med Food. 2015 Apr;18(4):497-502. doi: 10.1089/jmf.2013.0086. Epub 2014 Jan 29.

PMID:
24476216
7.

Crosstalk between immune cells and adipocytes requires both paracrine factors and cell contact to modify cytokine secretion.

Nitta CF, Orlando RA.

PLoS One. 2013 Oct 21;8(10):e77306. doi: 10.1371/journal.pone.0077306. eCollection 2013.

8.

The genetics of childhood obesity and interaction with dietary macronutrients.

Garver WS, Newman SB, Gonzales-Pacheco DM, Castillo JJ, Jelinek D, Heidenreich RA, Orlando RA.

Genes Nutr. 2013 May;8(3):271-87. doi: 10.1007/s12263-013-0339-5. Epub 2013 Mar 8.

9.

SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.

Sillerud LO, Solberg NO, Chamberlain R, Orlando RA, Heidrich JE, Brown DC, Brady CI, Vander Jagt TA, Garwood M, Vander Jagt DL.

J Alzheimers Dis. 2013;34(2):349-65. doi: 10.3233/JAD-121171.

10.

Da Vinci's notebook: a novel learning tool.

Orlando RA.

Med Educ. 2012 May;46(5):514-5. doi: 10.1111/j.1365-2923.2012.04228.x. No abstract available.

PMID:
22515772
11.

A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization.

Orlando RA, Gonzales AM, Royer RE, Deck LM, Vander Jagt DL.

PLoS One. 2012;7(3):e31869. doi: 10.1371/journal.pone.0031869. Epub 2012 Mar 19.

12.

Increased CD36 expression signals monocyte activation among patients with type 2 diabetes.

Sun Y, Scavini M, Orlando RA, Murata GH, Servilla KS, Tzamaloukas AH, Schrader R, Bedrick EJ, Burge MR, Abumrad NA, Zager PG.

Diabetes Care. 2010 Sep;33(9):2065-7. doi: 10.2337/dc10-0460. Epub 2010 Jun 14.

13.

Inhibition of nuclear factor kappaB activation and cyclooxygenase-2 expression by aqueous extracts of Hispanic medicinal herbs.

Orlando RA, Gonzales AM, Hunsaker LA, Franco CR, Royer RE, Vander Jagt DL, Vander Jagt DJ.

J Med Food. 2010 Aug;13(4):888-95. doi: 10.1089/jmf.2009.1128.

14.

A Jurkat transcriptional reporter cell line for high-throughput analysis of the nuclear factor-kappaB signaling pathway.

Gonzales AM, Orlando RA.

N Biotechnol. 2009 Nov 30;26(5):244-50. doi: 10.1016/j.nbt.2009.06.982. Epub 2009 Jul 1.

15.

Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.

Atkins E, Zamora S, Candia BJ, Baca A, Orlando RA.

Cytotechnology. 2005 Sep;49(1):25-37. doi: 10.1007/s10616-005-4637-7.

16.

Substituted trans-stilbenes can inhibit or enhance the TPA-induced up-regulation of activator protein-1.

Deck LM, Hunsaker LA, Gonzales AM, Orlando RA, Vander Jagt DL.

BMC Pharmacol. 2008 Nov 10;8:19. doi: 10.1186/1471-2210-8-19.

17.

Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes.

Gonzales AM, Orlando RA.

Nutr Metab (Lond). 2008 Jun 12;5:17. doi: 10.1186/1743-7075-5-17.

18.

Role of adipocyte-derived lipoprotein lipase in adipocyte hypertrophy.

Gonzales AM, Orlando RA.

Nutr Metab (Lond). 2007 Oct 30;4:22.

19.
21.

TPA-induced up-regulation of activator protein-1 can be inhibited or enhanced by analogs of the natural product curcumin.

Weber WM, Hunsaker LA, Gonzales AM, Heynekamp JJ, Orlando RA, Deck LM, Vander Jagt DL.

Biochem Pharmacol. 2006 Oct 16;72(8):928-40. Epub 2006 Aug 28.

PMID:
16934760
22.

Protease nexin-1 expression is altered in human breast cancer.

Candia BJ, Hines WC, Heaphy CM, Griffith JK, Orlando RA.

Cancer Cell Int. 2006 May 31;6:16.

23.

Cell surface heparan sulfate proteoglycans contribute to intracellular lipid accumulation in adipocytes.

Wilsie LC, Chanchani S, Navaratna D, Orlando RA.

Lipids Health Dis. 2005 Jan 6;4:2.

24.

Podocalyxin activates RhoA and induces actin reorganization through NHERF1 and Ezrin in MDCK cells.

Schmieder S, Nagai M, Orlando RA, Takeda T, Farquhar MG.

J Am Soc Nephrol. 2004 Sep;15(9):2289-98.

26.

Bioengineered implantation of megalin-expressing cells: a potential intracorporeal therapeutic model for uremic toxin protein clearance in renal failure.

Saito A, Kazama JJ, Iino N, Cho K, Sato N, Yamazaki H, Oyama Y, Takeda T, Orlando RA, Shimizu F, Tabata Y, Gejyo F.

J Am Soc Nephrol. 2003 Aug;14(8):2025-32.

28.
29.

The glomerular epithelial cell anti-adhesin podocalyxin associates with the actin cytoskeleton through interactions with ezrin.

Orlando RA, Takeda T, Zak B, Schmieder S, Benoit VM, McQuistan T, Furthmayr H, Farquhar MG.

J Am Soc Nephrol. 2001 Aug;12(8):1589-98.

30.

Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton.

Takeda T, McQuistan T, Orlando RA, Farquhar MG.

J Clin Invest. 2001 Jul;108(2):289-301.

32.

Characterization of ANKRA, a novel ankyrin repeat protein that interacts with the cytoplasmic domain of megalin.

Rader K, Orlando RA, Lou X, Farquhar MG.

J Am Soc Nephrol. 2000 Dec;11(12):2167-78.

33.
34.
35.

Megalin is an endocytic receptor for insulin.

Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG.

J Am Soc Nephrol. 1998 Oct;9(10):1759-66.

36.

All four putative ligand-binding domains in megalin contain pathogenic epitopes capable of inducing passive Heymann nephritis.

Yamazaki H, Ullrich R, Exner M, Saito A, Orlando RA, Kerjaschki D, Farquhar MG.

J Am Soc Nephrol. 1998 Sep;9(9):1638-44.

37.

Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis.

Kerjaschki D, Exner M, Ullrich R, Susani M, Curtiss LK, Witztum JL, Farquhar MG, Orlando RA.

J Clin Invest. 1997 Nov 1;100(9):2303-9.

38.

Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions.

Orlando RA, Exner M, Czekay RP, Yamazaki H, Saito A, Ullrich R, Kerjaschki D, Farquhar MG.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2368-73.

39.

Endocytic trafficking of megalin/RAP complexes: dissociation of the complexes in late endosomes.

Czekay RP, Orlando RA, Woodward L, Lundstrom M, Farquhar MG.

Mol Biol Cell. 1997 Mar;8(3):517-32.

41.

Mapping rat megalin: the second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation of immune deposits in Heymann nephritis.

Saito A, Yamazaki H, Rader K, Nakatani A, Ullrich R, Kerjaschki D, Orlando RA, Farquhar MG.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8601-5.

42.

Induction of passive Heymann nephritis with antibodies specific for a synthetic peptide derived from the receptor-associated protein.

Kerjaschki D, Ullrich R, Exner M, Orlando RA, Farquhar MG.

J Exp Med. 1996 May 1;183(5):2007-15.

44.

The Heymann nephritis antigenic complex: megalin (gp330) and RAP.

Farquhar MG, Saito A, Kerjaschki D, Orlando RA.

J Am Soc Nephrol. 1995 Jul;6(1):35-47. Review.

45.

The expression of megalin (gp330) and LRP diverges during F9 cell differentiation.

Czekay RP, Orlando RA, Woodward L, Adamson ED, Farquhar MG.

J Cell Sci. 1995 Apr;108 ( Pt 4):1433-41.

46.

gp330 and RAP: the Heymann nephritis antigenic complex.

Farquhar MG, Kerjaschki D, Lundstrom M, Orlando RA.

Ann N Y Acad Sci. 1994 Sep 10;737:96-113. Review.

PMID:
7944157
47.

Functional domains of the receptor-associated protein (RAP).

Orlando RA, Farquhar MG.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3161-5.

48.

Immunocytochemical and biochemical characterization of the Heymann nephritis antigenic complex in rat L2 yolk sac cells.

Lundstrom M, Orlando RA, Saedi MS, Woodward L, Kurihara H, Farquhar MG.

Am J Pathol. 1993 Nov;143(5):1423-35.

50.

Identification of a pathogenic epitope involved in initiation of Heymann nephritis.

Kerjaschki D, Ullrich R, Diem K, Pietromonaco S, Orlando RA, Farquhar MG.

Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11179-83.

Supplemental Content

Loading ...
Support Center